NEW YORK (GenomeWeb) – Adaptive Biotechnologies plans to collaborate with Amgen to develop and commercialize Adaptive's next-generation sequencing-based immune profiling assay, ClonoSeq, to assess minimal residual disease in patients with acute lymphoblastic leukemia, Adaptive said today.
As part of the collaboration, the companies plan to collect MRD data in order to establish validated thresholds of residual disease that can predict patient outcomes in ALL.
"We are excited to demonstrate through this collaboration that Adaptive's highly accurate and sensitive ClonoSeq assay can be used to give patients and clinicians a more reliable and validated resource to improve monitoring and management of ALL," Adaptive CEO Chad Robins said in a statement.
Adaptive launched ClonoSeq in 2013 as a laboratory-developed test for blood cancers. The company also plans to seek clearance from the US Food and Drug Administration for the assay.